|
|
 | | | |
- close
- close
- close
- close
| |||||||||
This excerpt taken from the ELN 6-K filed Mar 30, 2009. Senior
Management
Nigel Clerkin (35)
Senior Vice President, Finance and Group Controller
Mr. Clerkin was appointed senior vice president, finance
and group controller, in January 2004, having previously held a
number of financial and strategic planning positions since
joining Elan in January 1998. He is also our principal
accounting officer. Mr. Clerkin is a chartered accountant
and a graduate of Queen’s University Belfast.
Richard T. Collier (55)
Executive Vice President and General Counsel
Mr. Collier joined Elan as executive vice president and
general counsel in November 2004. Prior to joining Elan,
Mr. Collier was senior counsel at Morgan, Lewis &
Bockius LLP. Prior to joining Morgan Lewis, he was senior vice
president and general counsel at Pharmacia, after serving in
that position at Pharmacia & Upjohn. Prior to his
experience at Pharmacia, Mr. Collier spent 11 years at
Rhone-Poulenc Rorer, Inc. Previously, he was in private practice
after having served with the U.S. Federal Trade Commission
and U.S. Department of Justice. Mr. Collier is a
graduate of Temple University and earned his Juris Doctor at
Temple University.
William F. Daniel (57)
Executive Vice President and Company Secretary
Mr. Daniel was appointed a director of Elan in February
2003 and served until July 2007. He has served as the company
secretary since December 2001, having joined Elan in March 1994
as group financial controller. In July 1996, he was appointed
group vice president, finance, group controller and principal
accounting officer. From 1990 to 1992, Mr. Daniel was
financial director of Xtravision, plc. Mr. Daniel is a
chartered accountant and a graduate of University College Dublin.
Kathleen Martorano (47)
Executive Vice President, Strategic Human Resources
Ms. Martorano was appointed executive vice president,
strategic human resources, and a member of the office of the
chief executive officer, in January 2005. She joined Elan in May
2003 as senior vice president, corporate marketing and
communications. Prior to joining Elan, Ms. Martorano held
senior management positions at Merrill Lynch & Co.,
which she joined in 1996, and where she was most recently first
vice president of marketing and communications for the
International Private Client Group. Previously, she held senior
management positions with Salomon Brothers. Ms. Martorano
holds a Bachelor of Science degree from Villanova University.
Carlos V. Paya, MD, PhD (50)
President
Dr. Paya joined Elan as president in November 2008.
Dr. Paya joined Elan from Eli Lilly & Company,
where he was vice president, Lilly Research Laboratories, and
global leader of the Diabetes and Endocrine Platform,
responsible for the company’s franchise (insulin products).
He had been an executive with Lilly since 2001, gaining a wide
range of leadership experience in different therapeutic areas
and business strategy. Prior to his career at Lilly,
Dr. Paya had a
16-year
relationship with the Mayo Clinic in Rochester, Minnesota, which
began with his acceptance into the Mayo Graduate School of
Medicine in 1984 and concluded with a six-year tenure as
professor of medicine, Immunology and Pathology, and vice dean
of the Clinical Investigation Program. Dr. Paya’s
other responsibilities and positions at or associated with the
Mayo Clinic included two years as associate professor and senior
associate consulting staff, Infectious Diseases and Internal
Medicine, Pathology and Laboratory Medicine, and Immunology; and
four years as a research scientist at Institute Pasteur, Paris,
and as chief, Infectious Diseases Unit, Hospital
12 Octubre, Madrid, Spain.
Table of Contents
This excerpt taken from the ELN 20-F filed Feb 26, 2009. Senior
Management
Nigel Clerkin (35)
Senior Vice President, Finance and Group Controller
Mr. Clerkin was appointed senior vice president, finance
and group controller, in January 2004, having previously held a
number of financial and strategic planning positions since
joining Elan in January 1998. He is also our principal
accounting officer. Mr. Clerkin is a chartered accountant
and a graduate of Queen’s University Belfast.
Richard T. Collier (55)
Executive Vice President and General Counsel
Mr. Collier joined Elan as executive vice president and
general counsel in November 2004. Prior to joining Elan,
Mr. Collier was senior counsel at Morgan, Lewis &
Bockius LLP. Prior to joining Morgan Lewis, he was senior vice
president and general counsel at Pharmacia, after serving in
that position at Pharmacia & Upjohn. Prior to his
experience at Pharmacia, Mr. Collier spent 11 years at
Rhone-Poulenc Rorer, Inc. Previously, he was in private practice
after having served with the U.S. Federal Trade Commission
and U.S. Department of Justice. Mr. Collier is a
graduate of Temple University and earned his Juris Doctor at
Temple University.
William F. Daniel (56)
Executive Vice President and Company Secretary
Mr. Daniel was appointed a director of Elan in February
2003 and served until July 2007. He has served as the company
secretary since December 2001, having joined Elan in March 1994
as group financial controller. In July
Table of Contents
1996, he was appointed group vice president, finance, group
controller and principal accounting officer. From 1990 to 1992,
Mr. Daniel was financial director of Xtravision, plc.
Mr. Daniel is a chartered accountant and a graduate of
University College Dublin.
Kathleen Martorano (47)
Executive Vice President, Strategic Human Resources
Ms. Martorano was appointed executive vice president,
strategic human resources, and a member of the office of the
chief executive officer, in January 2005. She joined Elan in May
2003 as senior vice president, corporate marketing and
communications. Prior to joining Elan, Ms. Martorano held
senior management positions at Merrill Lynch & Co.,
which she joined in 1996, and where she was most recently first
vice president of marketing and communications for the
International Private Client Group. Previously, she held senior
management positions with Salomon Brothers. Ms. Martorano
holds a Bachelor of Science degree from Villanova University.
Carlos V. Paya, MD, PhD (50)
President
Dr. Paya joined Elan as president in November 2008.
Dr. Paya joined Elan from Eli Lilly & Company,
where he was vice president, Lilly Research Laboratories, and
global leader of the Diabetes and Endocrine Platform,
responsible for the company’s franchise (insulin products).
He had been an executive with Lilly since 2001, gaining a wide
range of leadership experience in different therapeutic areas
and business strategy. Prior to his career at Lilly,
Dr. Paya had a
16-year
relationship with the Mayo Clinic in Rochester, Minnesota, which
began with his acceptance into the Mayo Graduate School of
Medicine in 1984 and concluded with a six-year tenure as
professor of medicine, Immunology and Pathology, and vice dean
of the Clinical Investigation Program. Dr. Paya’s
other responsibilities and positions at or associated with the
Mayo Clinic included two years as associate professor and senior
associate consulting staff, Infectious Diseases and Internal
Medicine, Pathology and Laboratory Medicine, and Immunology; and
four years as a research scientist at Institute Pasteur, Paris,
and as chief, Infectious Diseases Unit, Hospital
12 Octubre, Madrid, Spain.
This excerpt taken from the ELN 20-F filed Feb 28, 2008. Senior
Management
Menghis Bairu, MD (47)
Senior Vice President, Head of International
Dr. Bairu was appointed senior vice president and head of
international for all of Elan’s biopharmaceutical
activities outside the United States in May 2007. He joined Elan
in 2004 and had served as vice president and head of global
medical affairs and as senior director in charge of the regional
medical scientists. Prior to joining Elan, Dr. Bairu worked
at Genentech, Inc. in various commercial, clinical and managed
care roles. He received his undergraduate degree in business
administration from Instituto VII Tecnico Commerciale in Milan,
Italy, and attended the Universita Statale, Facoltà di
Medicina e Chirurgia (Faculty of Medicine and Surgery) in
Milan, where he received his Medical Degree.
James Callaway, PhD (51)
Senior Vice President, Head of Immunotherapy AD Clinical Programs
Dr. Callaway was appointed senior vice president, head of
immunotherapy Alzheimer’s disease clinical programs, in
March 2004. Since joining Elan in 1995, Dr. Callaway has
held several senior positions, including interim head of global
development and vice president of biopharmaceutical development
services. Prior to joining Elan, he worked at Bayer
Pharmaceuticals. Dr. Callaway received his PhD in
biological chemistry from University of California, Los Angeles,
and a Bachelor of Science in chemistry from California State
University, Chico.
Nigel Clerkin (34)
Senior Vice President, Finance and Group Controller
Mr. Clerkin was appointed senior vice president, finance
and group controller in January 2004, having previously held a
number of financial and strategic planning positions since
joining Elan in January 1998. He is also our principal
accounting officer. Mr. Clerkin is a chartered accountant
and a graduate of Queen’s University Belfast.
Richard Collier (54)
Executive Vice President and General Counsel
Mr. Collier joined Elan as executive vice president and
general counsel in November 2004. Prior to joining Elan,
Mr. Collier was senior counsel at Morgan, Lewis &
Bockius LLP. Prior to joining Morgan Lewis, he was senior vice
president and general counsel at Pharmacia (now Pfizer), after
serving in that position at Pharmacia & Upjohn. Prior
to his experience at Pharmacia, Mr. Collier spent
11 years at Rhone-Poulenc Rorer, Inc. Previously, he was in
private practice after having served with the U.S. Federal
Trade Commission and U.S. Department of Justice.
Mr. Collier is a graduate of Temple University and earned
his Juris Doctor at Temple University.
William F. Daniel (55)
Executive Vice President and Company Secretary
Mr. Daniel was appointed a director of Elan in February
2003 and served until July 2007. He has served as the company
secretary since December 2001, having joined Elan in March 1994
as group financial controller. In July 1996, he was appointed
group vice president, finance, group controller and principal
accounting officer. From 1990 to 1992, Mr. Daniel was
financial director of Xtravision, plc. Mr. Daniel is a
chartered accountant and a graduate of University College Dublin.
Table of Contents
David W. Feigal, Jr, MD (58)
Senior Vice President, Head of Global Regulatory and Global Safety Surveillance
Dr. Feigal joined Elan as senior vice president, head of
global regulatory and global safety surveillance in November
2006. Prior to joining Elan, he served most recently as a
principal with NDA Partners, and prior thereto spent
12 years with the FDA. Before joining the FDA,
Dr. Feigal worked for 10 years within the academic and
hospital settings of the University of California in
San Diego, San Francisco and Davis. Dr. Feigal
holds an BA from University of Minnesota, an MD from Stanford
University and a Master of Public Health from the University of
California, Berkeley.
Allison Hulme, PhD (44)
Executive Vice President, Global Development
Dr. Hulme was appointed executive vice president, head of
global development, in May 2007. From 2005 to 2007,
Dr. Hulme was executive vice president, autoimmune,
Tysabri, global development. Previously, Dr. Hulme
held the positions of executive vice president, Tysabri
business enterprise, and senior vice president, head of
global development. Prior to joining Elan in October 1995,
Dr. Hulme held several positions in clinical research at
Glaxo Wellcome Pharmaceuticals (United Kingdom) and served as a
lecturer at Luton University. She holds a degree in science
from Luton University and earned her PhD from Cranfield
Institute of Technology.
Karen S. Kim (45)
Executive Vice President, Corporate Strategy & Alliances, Communications, Branding and Specialty Business Group
Ms. Kim was appointed executive vice president, corporate
strategy & alliances, communications, branding and
specialty business group, in January 2005. She joined Elan in
September 2003 as senior vice president, head of global
corporate strategy and strategic alliances. Prior to joining
Elan, Ms. Kim held senior management positions at Merrill
Lynch & Co., which she joined in 1998, and where she
was most recently head of client development in the
International Private Client Group. Previously she held senior
management positions at the Cambridge Group and The MAC
Group/Gemini Consulting. She is a graduate of Wellesley College
and earned her MBA from the Harvard Graduate School of Business
Administration.
Ivan Lieberburg, MD, PhD (58)
Executive Vice President and Chief Medical Officer
Dr. Lieberburg is executive vice president and chief
medical officer of Elan, where he has held a number of senior
positions, most recently senior vice president of research.
Prior to joining Athena Neurosciences in 1987,
Dr. Lieberburg held faculty positions at the Albert
Einstein College of Medicine and Mt. Sinai School of Medicine in
New York. He received an AB from Cornell University and earned
his PhD in Neurobiology from The Rockefeller University.
Dr. Lieberburg was a postdoctoral fellow in Neurobiology at
Rockefeller University. He earned his MD from the University of
Miami. Dr. Lieberburg was a research endocrine fellow at
the University of California, San Francisco.
Kathleen Martorano (46)
Executive Vice President, Strategic Human Resources
Ms. Martorano was appointed executive vice president,
strategic human resources, and a member of the office of the
chief executive officer, in January 2005. She joined Elan in May
2003 as senior vice president, corporate marketing and
communications. Prior to joining Elan, Ms. Martorano held
senior management positions at Merrill Lynch &
Co., which she joined in 1996, and where she was most recently
first vice president of marketing and communications for the
International Private Client Group. Previously, she held senior
management positions with Salomon Brothers. Ms. Martorano
holds a Bachelor of Science degree from Villanova University.
Johannes Roebers, PhD (47)
Senior Vice President, Head of Biologic Strategy, Planning and Operations
Dr. Roebers joined Elan as senior vice president, head of
biologic strategy, planning and operations, in July 2007. Prior
to joining Elan, Dr. Roebers worked at Genentech. He joined
Genentech when it acquired the Oceanside manufacturing facility
from Biogen Idec in 2005, as he had been Biogen Idec’s
project leader for design,
Table of Contents
construction and
start-up of
the facility since 2001. Before joining Biogen Idec,
Dr. Roebers spent 11 years with Bayer Corporation. He
received his Diplom-Ingenieur in mechanical engineering from
RWTH Aachen in Aachen, Germany, and his PhD in chemical
engineering from Clemson University.
Dale Schenk, PhD (50)
Executive Vice President and Chief Scientific Officer
Dr. Schenk was appointed Elan’s executive vice
president and chief scientific officer in September 2007. From
2003 to 2007, Dr. Schenk was senior vice president and
Elan’s chief scientific officer. From 1999 to 2003,
Dr. Schenk was senior vice president of discovery research
at Elan and, from 1998 to 1999, he was the company’s vice
president of neurobiology. Previously, Dr. Schenk was
director of neurobiology for Athena Neurosciences from 1994 to
1998. Earlier at Athena, from 1987 to 1994, Dr. Schenk
served as the leader of several research programs.
Dr. Schenk earned his bachelor’s degree in biology and
a PhD in physiology and pharmacology from the University of
California, San Diego.
Ted Yednock, PhD (50)
Executive Vice President, Head of Global Research
Dr. Yednock was appointed executive vice president, head of
global research, in September 2007. Dr. Yednock joined
Athena Neurosciences in 1990 to initiate work on MS. He has
contributed to a number of research efforts since that time in
the areas of both autoimmune and neurodegeneration, and has held
a number of scientific and management positions within the
organization, including senior vice president, head of global
research, and vice president, biology. He earned his
bachelor’s degree in biology and chemistry from the
University of Illinois and his PhD in immunology from the
University of California, San Francisco.
This excerpt taken from the ELN 6-K filed Mar 30, 2007. Senior
Management
Paul Breen (50)
Executive Vice President, Elan Drug Technologies
Mr. Breen joined Elan in July 2001. Prior to joining Elan,
he was vice president and joint managing director of Pfizer
Pharmaceuticals Ireland. Prior thereto, he was vice president
and managing director of Warner-Lambert Company’s Irish
operations. He is Chairman of the governing body of the Athlone
Institute of Technology. Mr. Breen holds a degree in
science and is a graduate of University College Dublin.
Nigel Clerkin (33)
Senior Vice President, Finance and Group Controller
Mr. Clerkin was appointed senior vice president, finance
and group controller in January 2004, having previously held a
number of financial and strategic planning positions since
joining Elan in January 1998. He is also our principal
accounting officer. Mr. Clerkin is a chartered accountant
and a graduate of Queen’s University Belfast.
Richard Collier (53)
Executive Vice President and General Counsel
Mr. Collier joined Elan as executive vice president and
general counsel in November 2004. Prior to joining Elan,
Mr. Collier was senior counsel at Morgan, Lewis &
Bockius LLP. Prior to joining Morgan Lewis, he was senior vice
president and general counsel at Pharmacia (now Pfizer), after
serving in that same position at Pharmacia & Upjohn.
Prior to his experience at Pharmacia, Mr. Collier spent
11 years at Rhone-Poulenc Rorer, Inc. Previously, he was in
private practice after having served with the US Federal Trade
Commission and US Department of Justice. Mr. Collier is a
graduate of Temple University and also earned his Juris Doctor
at Temple University.
David W. Feigal, Jr, MD (57)
Senior Vice President, Head of Global Regulatory and Global
Safety Surveillance
Elan Corporation, plc 2006 Annual
Report 51
Table of Contents
Dr. Feigal joined us as senior vice president, head of
global regulatory and global safety surveillance in November
2006. Prior to joining Elan, he served most recently as a
principal with NDA Partners, and prior thereto spent twelve
years with the FDA. Before joining the FDA, Dr. Feigal
worked for ten years within the academic and hospital settings
of the University of California in San Diego,
San Francisco and Davis. Dr. Feigal holds a BA from
University of Minnesota, an MD from Stanford University and a
Master of Public Health from the University of California,
Berkeley.
Allison Hulme, PhD (43)
Executive Vice President, Autoimmune, Tysabri, Global
Development
Dr. Hulme was appointed executive vice president,
autoimmune, Tysabri, global development, in January 2005.
Previously, Dr. Hulme held the positions of executive vice
president, Tysabri business enterprise, and senior vice
president, head of global development. Prior to joining Elan in
October 1995, Dr. Hulme held several positions in Clinical
Research at Glaxo Wellcome Pharmaceuticals (United Kingdom) and
served as a lecturer at Luton University. She holds a degree in
science from Luton University and earned her PhD from Cranfield
Institute of Technology.
Karen S. Kim (44)
Executive Vice President, Corporate Strategy &
Alliances, Communications, Branding and Specialty Business
Group
Ms. Kim was appointed executive vice president, corporate
strategy & alliances, communications, branding and
specialty group, in January 2005. She joined Elan in September
2003 as senior vice president, head of global corporate strategy
and strategic alliances. Prior to joining Elan, Ms. Kim
held senior management positions at Merrill Lynch &
Co., which she joined in 1998, and where she was most recently
head of Client Development in the International Private Client
Group. Previously she held senior management positions at the
Cambridge Group and The MAC Group/Gemini Consulting. She is a
graduate of Wellesley College and earned her MBA from the
Harvard Graduate School of Business Administration.
Ivan Lieberburg, MD, PhD (57)
Executive Vice President and Chief Medical Officer
Dr. Lieberburg is executive vice president and chief
medical officer of Elan, where he has held a number of senior
positions, most recently senior vice president of research.
Prior to joining Athena Neurosciences in 1987,
Dr. Lieberburg held faculty positions at the Albert
Einstein College of Medicine and Mt. Sinai School of Medicine in
New York. He received an AB from Cornell University and earned
his PhD in Neurobiology from The Rockefeller University.
Dr. Lieberburg was a Postdoctoral Fellow in Neurobiology at
Rockefeller University. He earned his MD from the University of
Miami. Dr. Lieberburg was a Research Endocrine Fellow at
the University of California, San Francisco.
Kathleen Martorano (45)
Executive Vice President, Strategic Human Resources
Ms. Martorano was appointed executive vice president,
strategic human resources, and a member of the office of the
chief executive officer, in January 2005. She joined Elan in May
2003 as senior vice president, corporate marketing &
communications. Prior to joining Elan, Ms. Martorano held
senior management positions at Merrill Lynch & Co.,
which she joined in 1996, and where she was most recently first
vice president of Marketing and Communications for the
International Private Client Group. Previously, she held senior
management positions with Salomon Brothers. Ms. Martorano
holds a Bachelor of Science degree from Villanova University.
Dale Schenk, PhD (49)
Senior Vice President and Chief Scientific Officer
Dr. Schenk was appointed Elan’s senior vice president
and Elan’s chief scientific officer in June 2003. From 1999
to 2003, Dr. Schenk was senior vice president of discovery
research at Elan, and from 1998 to 1999, he was the
company’s vice president of neurobiology. Previously,
Dr. Schenk was director of neurobiology for Athena
Neurosciences from 1994 to 1998. Earlier at Athena, from 1987 to
1994, Dr. Schenk served as the leader of several research
programmes. Dr. Schenk earned his Bachelor’s degree in
Biology and a PhD in Physiology and Pharmacology from the
University of California, San Diego.
Ted Yednock, PhD (49)
Senior Vice President, Head of Global Research
Dr. Yednock was appointed senior vice president, head of
global research, in September 2005. Dr. Yednock joined
Athena Neurosciences in 1990 to initiate work on MS. He has
contributed to a number of research efforts since that time in
the areas of both autoimmune and neurodegeneration, and has held
a number of scientific and management positions within the
organisation. Most recently, Dr. Yednock served as vice
president, biology. He earned his Bachelor’s degree in
Biology and Chemistry from the University of Illinois and his
PhD in Immunology from the University of California,
San Francisco.
52 Elan
Corporation, plc 2006 Annual Report
Table of Contents
This excerpt taken from the ELN 20-F filed Feb 28, 2007. Senior
Management
Paul Breen (50)
Executive Vice President, Elan Drug Technologies
Mr. Breen joined Elan in July 2001. Prior to
joining Elan, he was vice president and joint managing director
of Pfizer Pharmaceuticals Ireland. Prior thereto, he was vice
president and managing director of Warner-Lambert Company’s
Irish operations. He is Chairman of the governing body of the
Athlone Institute of Technology. Mr. Breen holds a degree
in science and is a graduate of University College Dublin.
Nigel Clerkin (33)
Senior Vice President, Finance and Group Controller
Mr. Clerkin was appointed senior vice president, finance
and group controller in January 2004, having previously held a
number of financial and strategic planning positions since
joining Elan in January 1998. He is also our principal
accounting officer. Mr. Clerkin is a chartered accountant
and a graduate of Queen’s University Belfast.
Richard Collier (53)
Executive Vice President and General Counsel
Mr. Collier joined Elan as executive vice president and
general counsel in November 2004. Prior to joining Elan,
Mr. Collier was senior counsel at Morgan, Lewis &
Bockius LLP. Prior to joining Morgan Lewis, he was senior vice
president and general counsel at Pharmacia (now Pfizer), after
serving in that same position at Pharmacia & Upjohn.
Prior to his experience at Pharmacia, Mr. Collier spent
11 years at Rhone-Poulenc Rorer, Inc. Previously, he was in
Table of Contents
private practice after having served with the US Federal Trade
Commission and US Department of Justice. Mr. Collier is a
graduate of Temple University and also earned his Juris Doctor
at Temple University.
David W. Feigal, Jr, MD (57)
Senior Vice President, Head of Global Regulatory and Global Safety Surveillance
Dr. Feigal joined us as senior vice president, head of
global regulatory and global safety surveillance in November
2006. Prior to joining Elan, he served most recently as a
principal with NDA Partners, and prior thereto spent twelve
years with the FDA. Before joining the FDA, Dr. Feigal
worked for ten years within the academic and hospital settings
of the University of California in San Diego,
San Francisco and Davis. Dr. Feigal holds a BA from
University of Minnesota, an MD from Stanford University and a
Master of Public Health from the University of California,
Berkeley.
Allison Hulme, PhD (43)
Executive Vice President, Autoimmune, Tysabri, Global
Development
Dr. Hulme was appointed executive vice president,
autoimmune, Tysabri, global development, in January 2005.
Previously, Dr. Hulme held the positions of executive vice
president, Tysabri business enterprise, and senior vice
president, head of global development. Prior to joining Elan in
October 1995, Dr. Hulme held several positions in Clinical
Research at Glaxo Wellcome Pharmaceuticals (United Kingdom) and
served as a lecturer at Luton University. She holds a degree in
science from Luton University and earned her PhD from Cranfield
Institute of Technology.
Karen S. Kim (44)
Executive Vice President, Corporate Strategy &
Alliances, Communications, Branding and Specialty Business
Group
Ms. Kim was appointed executive vice president, corporate
strategy & alliances, communications, branding and
specialty group, in January 2005. She joined Elan in September
2003 as senior vice president, head of global corporate strategy
and strategic alliances. Prior to joining Elan, Ms. Kim
held senior management positions at Merrill Lynch &
Co., which she joined in 1998, and where she was most recently
head of Client Development in the International Private Client
Group. Previously she held senior management positions at the
Cambridge Group and The MAC Group/Gemini Consulting. She is a
graduate of Wellesley College and earned her MBA from the
Harvard Graduate School of Business Administration.
Ivan Lieberburg, MD, PhD (57)
Executive Vice President and Chief Medical Officer
Dr. Lieberburg is executive vice president and chief
medical officer of Elan, where he has held a number of senior
positions, most recently senior vice president of research.
Prior to joining Athena Neurosciences in 1987,
Dr. Lieberburg held faculty positions at the Albert
Einstein College of Medicine and Mt. Sinai School of Medicine in
New York. He received an AB from Cornell University and earned
his PhD in Neurobiology from The Rockefeller University.
Dr. Lieberburg was a Postdoctoral Fellow in Neurobiology at
Rockefeller University. He earned his MD from the University of
Miami. Dr. Lieberburg was a Research Endocrine Fellow at
the University of California, San Francisco.
Kathleen Martorano (45)
Executive Vice President, Strategic Human Resources
Ms. Martorano was appointed executive vice president,
strategic human resources, and a member of the office of the
chief executive officer, in January 2005. She joined Elan in May
2003 as senior vice president, corporate marketing &
communications. Prior to joining Elan, Ms. Martorano held
senior management positions at Merrill Lynch & Co.,
which she joined in 1996, and where she was most recently first
vice president of Marketing and Communications for the
International Private Client Group. Previously, she held senior
management positions with Salomon Brothers. Ms. Martorano
holds a Bachelor of Science degree from Villanova University.
Dale Schenk, PhD (49)
Senior Vice President and Chief Scientific Officer
Dr. Schenk was appointed Elan’s senior vice president
and Elan’s chief scientific officer in June 2003. From 1999
to 2003, Dr. Schenk was senior vice president of discovery
research at Elan, and from 1998 to 1999, he was the
company’s vice president of neurobiology. Previously,
Dr. Schenk was director of neurobiology for Athena
Neurosciences from 1994 to 1998. Earlier at Athena, from 1987 to
1994, Dr. Schenk served as the leader of several research
programs. Dr. Schenk earned his Bachelor’s degree in
Biology and a PhD in Physiology and Pharmacology from the
University of California, San Diego.
Table of Contents
Ted Yednock, PhD (49)
Senior Vice President, Head of Global Research
Dr. Yednock was appointed senior vice president, head of
global research, in September 2005. Dr. Yednock joined
Athena Neurosciences in 1990 to initiate work on MS. He has
contributed to a number of research efforts since that time in
the areas of both autoimmune and neurodegeneration, and has held
a number of scientific and management positions within the
organization. Most recently, Dr. Yednock served as vice
president, biology. He earned his Bachelor’s degree in
Biology and Chemistry from the University of Illinois and his
PhD in Immunology from the University of California,
San Francisco.
This excerpt taken from the ELN 6-K filed Mar 31, 2006. Senior Management
Kelly Martin
President and chief executive officer
Paul Breen
Executive vice president, elan drug technologies
Nigel Clerkin
Senior vice president, finance and group controller
Richard Collier
Executive vice president and general counsel
Shane Cooke
Executive vice president and chief financial officer
William F. Daniel
Executive vice president and company secretary
Lars Ekman, MD, PhD
Executive vice president and president, global R&D and
head of neurodegeneration franchise
Allison Hulme, PhD
Executive vice president, autoimmune, Tysabri, global
development
Karen S. Kim
Executive vice president, corporate strategy and alliances,
communications, branding and specialty business group
Ivan Lieberburg, MD, PhD
Executive vice president and chief medical officer
Kathleen Martorano
Executive vice president, strategic human resources
Dale Schenk, PhD
Senior vice president and chief scientific officer
Ted Yednock, PhD
Senior vice president, head of global research
Elan Corporation, plc 2005 Annual Report 171
Table of Contents
Table of Contents
This excerpt taken from the ELN 20-F filed Mar 30, 2006. Senior
Management
Paul Breen (49) is executive vice president, EDT. He
joined Elan in July 2001. Prior to joining Elan, he was vice
president and joint managing director of Pfizer Pharmaceuticals
Ireland. Prior thereto, he was vice president and managing
director of Warner-Lambert Company’s Irish operations. He
is Chairman of the governing body of the Athlone Institute of
Technology. Mr. Breen holds a degree in science and is a
graduate of University College Dublin.
Nigel Clerkin (32) was appointed senior vice
president, finance and group controller in January 2004, having
previously held a number of financial and strategic planning
positions since joining Elan in January 1998. He is also our
principal accounting officer. Mr. Clerkin is a chartered
accountant and a graduate of Queen’s University Belfast.
Richard Collier (52) joined Elan as executive vice
president and general counsel in November 2004. Prior to joining
Elan, Mr. Collier was senior counsel at Morgan,
Lewis & Bockius LLP. Prior to joining Morgan Lewis, he
was senior vice president and general counsel at Pharmacia (now
Pfizer), after serving in that same position at
Pharmacia & Upjohn. Prior to his experience at
Pharmacia, Mr. Collier spent 11 years at Rhone-Poulenc
Rorer, Inc. Previously, he was in private practice after having
served with the U.S. Federal Trade Commission and
U.S. Department of Justice. Mr. Collier is a graduate
of Temple University and also earned his Juris Doctor at Temple
University.
Allison Hulme, PhD (42) was appointed executive vice
president, autoimmune, Tysabri, global development, in
January 2005. Previously, Dr. Hulme held the positions of
executive vice president, Tysabri business enterprise,
and senior vice president, head of global development. Prior to
joining Elan in October 1995, Dr. Hulme held several
positions in Clinical Research at Glaxo Wellcome Pharmaceuticals
(United Kingdom) and served as Lecturer at Luton University. She
holds a degree in science from Luton University and earned her
PhD from Cranfield Institute of Technology.
Karen S. Kim (43) was appointed executive vice
president, corporate strategy & alliances, communications,
branding and specialty group, in January 2005. She joined Elan
in September 2003 as senior vice president, head of global
corporate strategy and strategic alliances. Prior to joining
Elan, Ms. Kim held senior management positions at Merrill
Lynch & Co., which she joined in 1998, and where she
was most recently head of Client Development in the
International Private Client Group. Previously she held senior
management positions at the Cambridge Group and
Table of Contents
The MAC Group/Gemini Consulting. She is a graduate of Wellesley
College and earned her MBA from the Harvard Graduate School of
Business Administration.
Ivan Lieberburg, MD, PhD (56) is executive vice
president and chief medical officer of Elan, where he has held a
number of senior positions, most recently senior vice president
of research. Prior to joining Athena Neurosciences in 1987,
Dr. Lieberburg held faculty positions at the Albert
Einstein College of Medicine and Mt. Sinai School of Medicine in
New York. He received an AB from Cornell University and earned
his PhD in Neurobiology from The Rockefeller University.
Dr. Lieberburg was a Postdoctoral Fellow in Neurobiology at
Rockefeller University. He earned his MD from the University of
Miami. Dr. Lieberburg was a Research Endocrine Fellow at the
University of California, San Francisco.
Kathleen Martorano (44) was appointed executive vice
president, strategic human resources, and a member of the office
of the chief executive officer, in January 2005. She joined Elan
in May 2003 as senior vice president, corporate
marketing & communications. Prior to joining Elan,
Ms. Martorano held senior management positions at Merrill
Lynch & Co., which she joined in 1996, and where she
was most recently first vice president of Marketing and
Communications for the International Private Client Group.
Previously, she held senior management positions with Salomon
Brothers. Ms. Martorano holds a Bachelor of Science degree
from Villanova University.
Dale Schenk, PhD (48) was appointed senior vice
president and Elan’s chief scientific officer in June 2003.
From 1999 to 2003, Dr. Schenk was senior vice president of
discovery research at Elan, and from 1998 to 1999, he was the
company’s vice president of neurobiology. Previously,
Dr. Schenk was director of neurobiology for
Athena Neurosciences from 1994 to 1998. Earlier at Athena,
from 1987 to 1994, Dr. Schenk served as the leader of
several research programs. Dr. Schenk earned his
Bachelor’s degree in Biology from the University of
California, San Diego and a PhD in Physiology and
Pharmacology from the University of California, San Diego.
Ted Yednock, PhD (48) was appointed senior vice
president, head of global research, in September 2005.
Dr. Yednock joined Athena Neurosciences in 1990 to initiate
work on MS. He has contributed to a number of research efforts
since that time in the areas of both autoimmune and
neurodegeneration, and has held a number of scientific and
management positions within the organization. Most recently,
Dr. Yednock served as vice president, biology. He earned
his Bachelor’s degree in Biology and Chemistry from the
University of Illinois and his PhD in Immunology from the
University of California, San Francisco.
Officers serve at the discretion of the board of directors. No
director or officer has a family relationship with any other
director or officer.
| EXCERPTS ON THIS PAGE:
|
| |||||||
